ChemioCare gets DEA clearance to introduce dronabinol patch for cancer patients
ChemioCare USA Inc, a private biotech company focusing on cancer care, announced Friday that its exclusive development partner, Transdermal Research Pharm Laboratories, is now authorized by the US Drug Enforcement Administration (DEA) to handle Schedule 1 controlled substances. Transdermal’s successful registration with the DEA cracks the door open for the company to begin the formula development of a dronabinol transdermal patch, CMIO-DRONAB, which contains THC, a therapy which ChemioCare is looking to introduce in parallel. The DEA registration also offers an opportunity to research additional uses for dronabinol, a component of marijuana, ChemioCare said. “Advancing our dronabinol program is another development milestone for our company,” ChemioCare CEO Pedro Lichtinger said in a statement.”We have made significant progress establishing unique profiles for each patch, all are driven by on-label superiority.” READ: ChemioCare USA appoints three new members to board with eye toward going public in 2019 ChemioCare, based in New York, specializes in neutralizing chemotherapy-induced nausea and vomiting through its own transdermal patch technology. Its management is looking to take the company public in the first half of next year. Its other transdermal patches include its Olanzapine and Dexamethasone patches, CMIO-OLANZ and CMIO-DEX. CMIO-OLANZ, which relies on a seven-day transdermal delivery system, is the first product in development for PARP inhibitor-induced nausea and vomiting. CMIO-DEX, which also relies on a seven-day delivery, is used to control swelling and edema in brain cancer and brain surgery. Dexamethasone is highly-effective, but can, unfortunately, cause severe side effects. Another five-day patch, CMIO-ONDAN, delivers ondansetron and is a 5HT3 receptor antagonist, which treats chemotherapy-induced nausea and vomiting. Both CMIO-ONDAN and CMIO-OLANZ are set to enter Phase 3 clinical programs next year.
Originally post by Ellen Kelleher, Proactive Investors - email@example.com